WaveMan
WaveMan · Company
IVA · Inventiva S.A.
> Search tickers & screens ⌘K
LIVE
← All companies

IVA Inventiva (IVA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001756594
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
66
13F, latest reported quarter

Inventiva insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Inventiva S.A. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.

Insider
Filed
Shares
Value
Since filing

no insider purchases or sales on record

0 transactions on record
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
66 funds bought in last quarter
more than 54% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
5.1% of the float short (float per yahoo 2026-10-26) · 3.3 days to cover · settled 2026-09-30
below 53% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IVA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns IVA: institutional holders (13F)

13F holdings, latest reported quarter
$30.9M
$23.9M
3,633,181 sh
$13.7M

Congress trades in IVA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IVA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

IVA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Propel Opportunities ETF
$1.2M position · as of 2026-06-30
1.5%
Franklin Biotechnology Discovery Fund
$4.5M position · as of 2026-07-31
0.4%
Harbor Health Care ETF
$152.3K position · as of 2026-07-31
0.4%
Fidelity Advisor Biotechnology Fund
$3.1M position · as of 2026-07-31
0.1%
Fidelity Small Cap Stock K6 Fund
$10.8K position · as of 2026-07-31
0.1%
Fidelity Small Cap Stock Fund
$691.7K position · as of 2026-07-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 66 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Same sector, ranked by filing activity
Sector by SEC SIC code

IVA financials

Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2024-122023-122022-122021-12
Net income-$184.2M-$110.4M-$54.3M-$49.6M
SEC XBRL, fiscal years, as known on 2026-10-27

IVA Stock Sonar score 2/7 axes

Find similar shapesCompare
Institutional and government
54
Inputs
  • Funds adding, latest quarter66 · 54 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
58
Inputs
  • Short interest, % of float+5.1% · 58 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing